| Stock Report |
 |
 |
 |
 |
 |
|
18 January, 2010 (16:00:00 AEST) Cytopia [S&P/ASX 200 Health Care] drops to three-month high on spectacular volume January 18, 2010 16:00:00 AEST Cytopia (CYT.AU), Australia's 18th largest biotechnology company by market capitalisation, traded at its 66-day high of 14.0c during the day, but closed lower at 13.0c. The stock price fell 0.50c (or 3.7%) to close at 13.0c, ending a four-day streak of rises. Compared with the All Ordinaries index, which rose 6.6 points (or 0.1%) on the day, this was a relative price change of -3.8%.
PRICE VOLUME DYNAMICS Volatility: the stock traded between an intraday low of 13.0c and three-month high of 14.0c, suggesting a trading opportunity between peaks and troughs. Today its volatility of 7.7% was 3.9 times its average volatility of 2.0%. A price fall on high volatility is a bearish signal. Moving average price (MAP): the price to 200-day MAP ratio is 1.3, a bullish indicator. The stock is trading above both its MAPs at 10.0c for the 200-day MAP and 10.0c for the 50-day MAP, another bullish indicator. Relativities: today its percentile rank in the Australian market was 13. In the Australian market of 1,441 stocks traded today, the stock has a 6-month relative strength of 75 which means it has outperformed 75% of the market. Also, the relative strength percentile is improving at 75 for 6 months, 86 for 3 months and 95 for 1 month. Volume and turnover period: there were 2,232,400 shares worth $298,001 traded. The volume was 18.9 times average trading of 118,299 shares. The turnover rate in the 12 months to date was 37.6% (or a turnover period of 2 years 7 months). % Discount to high: the last price is at a discount of 18.8% to the 12-month high of 16.0c five months ago on 04 Sep, 2009. Volume weighted price (VWP): the price is at a premium of 5.9% to the 1-month volume weighted average price of 12.0c. Given that this premium has exceeded 5.9% forty-eight times and been under 5.9% eighteen times in the last year, the upside:downside probability is estimated at 48:18 or 2.7:1. Rises to Falls: In the last three months the number of rises outnumbered falls 21:12 or 1.8:1. PRICE PERFORMANCE RANK IN INDEX AND SECTORS The stock is in 1 index and 2 sectors : The stock's fall was in keeping with the trend set by the Total Australian Market of 1441 stocks traded today, which was down 33.1 points or 0.2% to 13,602.2 The stock went against the trend set by the following index and sector: Biotechnology sector of 23 stocks traded today, which was up 12.0 points or 0.2% to 6,844.1, All Ordinaries index which was up 6.6 points or 0.1% to 4,936.
RELATIVE VALUATION INDICATORS [RVI] FUNDAMENTAL ANALYSIS Bullish Signals: - Price/Sales of 2.63 versus sector average of 57.9 and market average of 15.4. - The Price to Book of 3.6 lower than average of 11.7 for the Total Australian Market. Bearish Signals: - Return on Equity of -130.2% versus sector average of 42.4% and market average of 18.0%. - Return on Assets of -102.7% versus sector average of 32.7% and market average of 6.6%. RELATIVE VALUATION INDICATORS [RVI] TECHNICAL ANALYSIS Bullish Signals: - The price soared 13.0% in the last week and 41.3% in the last month. - This has been propped up by strong volume of 7.9 times average for the week and 5.9 times average for the month. - Compared with the All Ordinaries index which rose 5.7% for the month, this represented a relative price increase of 35.6% for the month. - In the Australian market of 1,441 stocks traded today, the stock has a 6-month relative strength of 75 indicating it has outperformed 75% of the market. - Also, the relative strength percentile is improving at 75 for 6 months, 86 for 3 months and 95 for 1 month. - The stock is trading above both its MAPs at 10.0c for the 200-day MAP and 10.0c for the 50-day MAP. SHAREHOLDER RETURNS Trailing one week: the stock rose four times (80% of the time) and fell once (20% of the time). The volume was 7.9 times average trading of 591,495 shares. The value of $1,000 invested a week ago is $1,238 [vs $991 for the All Ordinaries index], for a capital gain of $238(or rise of 23.8%). Trailing one month: the stock rose nine times (50% of the time), was unchanged six times (33% of the time) and fell three times (17% of the time). The volume was 5.9 times average trading of 2,602,578 shares. The value of $1,000 invested a month ago is $1,413 [vs $1,057 for the All Ordinaries index], for a capital gain of $413(or rise of 41.3%). Trailing one year: the value of $1,000 invested one year ago is $929 [vs $1,448 for the All Ordinaries index], for a capital loss of $71. The total return to shareholders for 1 year is -7.1%. Trailing five years: the value of $1,000 invested five years ago is $213, for a capital loss of $787.
FINANCIALS Annual Report for the year ended June 30, 2009 (year-on-year comparisons with previous corresponding period)- Favourable Changes: total liabilities to total assets down 5.23% to 0.2. Unfavourable Changes: total revenue down 4.82% to $A4.2m ($US3.4m); loss of $A6.5m ($US5.3m); EPS reduced 19.79% to $A-0.08 (US-6.23c); losses in all of the last 5 years; current ratio down 9.03% to 3.3; Net tangible assets per share down 67.24% to $A0.0 (US2.9c); operating cash flow is negative; total number of shares outstanding up 0.09% to 84,691,304; Working capital to total assets down 16.22% to 46.8%. Major Common Size Ratios: total current assets to total assets down from 77.58% to 67.59%; cash to total assets down from 75.54% to 62.61%; total non current assets to total assets up from 22.42% to 32.41%; intangibles to total assets up from 13.89% to 30.83%; fixed assets to total assets down from 8.53% to 1.58%. MARKET SHARE Cytopia vs Biotechnology sector [Biotechnology sector Total in Brackets] Revenue of $4.2 million[1.3% of aggregate sector revenue of $325.7 million; down from 1.8% in the previous year.] FUNDAMENTALS P/S: the price/sales ratio is 2.6. Price to NTA: The net tangible asset backing per share is 3.60c. The price to net tangible asset backing per share is 3.6.
ISSUED CAPITAL Based on 84,691,304 issued shares the market capitalisation is $11 million. It is Australia's 32nd largest Biotechnology company by assets. ACTIVITIES Cytopia Limited (CYT) is a biotechnology company focused on discovery and development of new drugs to treat cancer, immune disorders and cardiovascular diseases. CYT has an exclusive license from the Ludwig Institute to several kinases (JAK1 and JAK2) for Cancer Research. CYT also is a registered Pooled Development Fund. TOP MANAGEMENT The chief executive officer is David Knox. REPORTED BUYING Reported Buying: December 29: Cytopia substantial shareholder buys Cytopia (CYT.AU) substantial shareholder Ubs Nominees bought 8,038,305 shares worth approximately $803,830.5 on December 24, 2009 and now holds 16,076,610. The last price was 10.0c. BUSINESS NEWS ROUND UP The last 5 snippets from News Bites are: December 29: UBS Nominees buys 8m Cytopia shares UBS Nominees, as prime broker for hedge funds, bought 8,038,305 Cytopia shares on December 24, becoming a substantial holder with 8,038,305 shares (9.49%). December 22: Monterrey Investment buys 7.9m Cytopia shares Monterrey Investment Management bought 7,901,079 Cytopia shares between December 10 and 22, becoming a substantial shareholder with 7,901,079 shares (9.3%). October 26: Cytopia director resigns Cytopia Ltd director Roderick Lyle resigned on October 19, 2009.He holds no securities. October 19: Cytopia director retires Cytopia Ltd director Roderick Lyle retired on October 19, 2009 due to ill health. September 30: Cytopia extends JAK2 US patent Cytopia Ltd has extended its patent protection over the validated JAK2 clinical target with another patent in the US for the treatment of myeloproliferative disorders. Cytopia holds the exclusive licence to a family of patents for the drug targets JAK1 and JAK2. The issuance of US patent number 7593820 augments this coverage by providing protection for the claimed methods of selecting or designing a compound which interacts with JAK2.Cytopia has appointed Ashley Arnott as chief financial officer and company secretary following the resignation of Gavan Flower. Currency Conversion: Australian Dollar AUD 1 = US$ 0.9224 [or US$1=AUD 1.08]; Against the US$ the AUD was unchanged for the day; strengthened 0.2% for the week; advanced 4.4% for the month; soared 20.9% in the past year. $1 = 100c. Source: www.BuySellSignals.com |